XOMA – xoma royalty corporation (US:NASDAQ)

News

XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com